SCHEMBL705681

SCHEMBL705681

O=C1c2ccccc2C(=O)c2c1cc(O)c(CO)c2O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 4/20 0.67
MCL1 Q07820 4/20 0.67
MEN1 O00255 4/20 0.54
MAOA P21397 4/20 0.54
KMT2A Q03164 4/20 0.54
MAPT P10636 3/20 0.54
KDM4E B2RXH2 2/20 0.54
ALDH1A1 P00352 2/20 0.54
CYP3A4 P08684 2/20 0.54
HPGD P15428 2/20 0.54
ALOX15 P16050 2/20 0.54
ALOX12 P18054 2/20 0.54
MAPK1 P28482 2/20 0.54
RECQL P46063 2/20 0.54
DAPK1 P53355 2/20 0.54
CYP1B1 Q16678 2/20 0.54
HSD17B10 Q99714 2/20 0.54
APEX1 P27695 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
PTPN1 P18031 4/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29632886 1.00 BCL2 (0.67) BCL2MCL1MEN1MAOAKMT2A
SCHEMBL30614616 0.86 TTR (0.62) BCL2MCL1MEN1MAOAKMT2A
SCHEMBL30040402 0.85 BCL2 (0.56) BCL2MCL1MEN1MAOAKMT2A
SCHEMBL23199018 0.83 BCL2 (0.61) BCL2MCL1MEN1MAOAKMT2A
SCHEMBL29883912 0.82 MEN1 (0.55) BCL2MCL1MEN1MAOAKMT2A
SCHEMBL31139082 0.81 BCL2 (0.59) BCL2MCL1MEN1MAOAKMT2A
SCHEMBL30038906 0.81 BCL2 (0.59) BCL2MCL1MEN1MAOAKMT2A
SCHEMBL16227056 0.81 BCL2 (0.59) BCL2MCL1MEN1MAOAKMT2A
SCHEMBL17867273 0.81 BCL2 (0.64) BCL2MCL1MEN1MAOAKMT2A
SCHEMBL555230 0.80 BCL2 (1.00) BCL2MCL1MEN1MAOAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3888670-B1 DRUG FOR TREATING LEUKOPENIA, PREPARATION METHOD THEREFOR AND USE THEREOF MONYAN PHARMACEUTICAL CO LTD (CN) 2025-12-24 EP claimed
EP-4438281-A1 DIP-TINTING OPHTHALMIC LENSES WITH NATURAL DYES Essilor International (FR) 2024-10-02 EP claimed
US-11801280-B2 Drug for treating leukopenia, preparation method thereof and use thereof HUBEI MONYAN PHARMACEUTICAL CO., LTD. (CN) 2023-10-31 US claimed
CN-115245533-B Application of Nanshan flower root extract in treating pulmonary fibrosis 中国医学科学院药物研究所 2023-07-28 CN claimed
WO-2022228095-A1 APPLICATION OF PRISMATOMERIS CONNATA Y. Z. RUAN ROOT EXTRACT IN PREPARATION OF MEDICINE FOR TREATING PULMONARY FIBROSIS 中国医学科学院药物研究所 2022-11-03 WO claimed
CN-115245533-A Application of south mountain flower root extract in pulmonary fibrosis treatment 中国医学科学院药物研究所 2022-10-28 CN claimed
CN-112014481-B Detection method of raw white oral liquid fingerprint spectrum 湖北梦阳药业股份有限公司 2022-10-25 CN claimed
CN-112007114-B Medicine for treating leucopenia and preparation method and application thereof 湖北梦阳药业股份有限公司 2022-05-13 CN claimed
EP-3943085-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2022-01-26 EP claimed
CN-108318311-B Hard bone specific calcium fluorescent staining method and application thereof 复旦大学 2022-01-18 CN claimed
CN-112007114-A Medicine for treating leucopenia and preparation method and application thereof 湖北梦阳药业股份有限公司 2020-12-01 CN claimed
CN-111840189-A Production process of black garlic moisturizing cream 山东钰财农业发展有限公司 2020-10-30 CN claimed
WO-2015144617-A1 METHOD FOR PREPARING A PURIFIED MADDER ROOT EXTRACT RUBIA EXPLOITATIE B.V. (NL) 2015-10-01 WO claimed
EP-2924076-A1 Method for preparing a purified madder root extract Rubia Exploitatie B.V. (NL) 2015-09-30 EP claimed
US-20110033525-A1 Diterpene Glycosides as Natural Solubilizers BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE 2011-02-10 US claimed
EP-2276463-A2 DITERPENE GLYCOSIDES AS NATURAL SOLUBILIZERS Board of Supervisors of Lousiana State University (US) 2011-01-26 EP claimed
WO-2009126950-A2 DITERPENE GLYCOSIDES AS NATURAL SOLUBILIZERS BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2009-10-15 WO claimed
US-20030082101-A1 Accelerators for increasing the rate of formation of free radicals and reactive oxygen species CAVALIER DISCOVERY 2003-05-01 US claimed
WO-2002100478-A9 ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES CAVALIER DISCOVERY (US) 2003-03-27 WO claimed
WO-2002100478-A2 ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES CAVALIER DISCOVERY (US) 2002-12-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030082101-A1 Accelerators for increasing the rate of formation of free radicals and reactive oxygen species SOD1, SOD3, APEX1 BCL2 410/4885MCL1 347/4885MEN1 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.